动物造模,诱发性炎性肠病 z-bio 2021-04-29 600

　　Objective: To investigate the therapeutic effect of anti-complement 5a receptor (C5aR) antibody combined with allicin on inflammatory bowel disease (IBD) in rats.

　　Method: IBD male rats induced by 802,4,6-trinitrobenzene sulfonic acid (TNBS) were divided into four groups: model control group, anti-C5aR antibody treatment group, alixin treatment group and anti-C5aR antibody treatment group. Are divided randomly. C5aR antibody combined with allicin treatment group; another 20 male rats served as normal control group. 14 days before and after the forced feeding, the weight change and survival rate of the rats were counted to detect the levels of interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) in the rat serum, and general measures were taken. Colon tissue analysis. Observation and pathological scoring.

　　Result: The rats treated with the combination of anti-C5aR antibody and allicin had higher body weight and survival rate than other treatment groups, and higher serum inflammatory factor II-6 and TNF-α expression levels in the rats. There is a clear trend of regression; the histopathological score of the colon also shows that the efficacy of the combined treatment group is significantly better than that of the other treatment groups (P\u003c0.05).

　　Conclusion: The combination of anti-C5aR antibody and allicin is an effective method to treat TNBS-induced IBD, and its therapeutic effect is better than using anti-C5aR antibody or allicin alone.